

Streamline  
Health®

First Quarter 2022 Earnings Presentation  
Nasdaq: STRM



# Disclosure Statement

## **SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE**


This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.

## **TRADEMARKS**

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners

# First Quarter 2022 & Recent Highlights







**\$8.9M** Fiscal Q1 2022 New Bookings as of April 30, 2022

**Completed first successful RevID sale under Cerner VAR**

# eValuator Solutions Update

---

-  New leadership with Ben Stilwill as President & CEO, eValuator and Amy Sebero as Chief Growth Officer, eValuator to lead the growth of eValuator Solutions
-  Successfully implementing new features addressing customer pain points
-  Recently entered beta phase for our professional-fee eValuator offering
-  Return to in-person meetings signals changing environment

# Avelead Update

---

- **EHR-agnostic** suite of revenue cycle solutions that help healthcare providers capture **100%** of the revenue they've earned
- Flagship **RevID** solution compares posted charges to clinical information and is an ideal complement to eValuator
- Signed an eight-hospital, Cerner-EHR health system in Michigan
- Signed our first MEDITECH-EHR customer
- Prioritizing improvements to innovation and service components
- Continuing to leverage opportunities through channel partner, Cerner

# Financial Results

## Income Statement

	Three Months Ended April 30, 2022	Three Months Ended April 30, 2021
Revenue	\$5.9M	\$3.0M
Operating Expenses	\$9.1M	\$5.4M
Income (Loss) From Continuing Operations	(\$2.8M)	(\$2.5M)
Net Income/(Loss)	(\$2.8M)	(\$2.1M)
Adj. EBITDA*	(\$1.7M)	(\$0.7M)

\*Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see our press release for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.




# Financial Results


## Balance Sheet

	As of April 30, 2022	As of January 31, 2022
Cash & Cash Equivalents	\$8.0M	\$9.9M
Total Current Assets	\$13.7M	\$15.1M
Total Current Liabilities	\$15.0M	\$13.5M
Total Bank Debt Outstanding	\$10.0M	\$10.0M

# Looking Forward

---

-  Project continued growth of recurring SaaS revenue as a percentage of total revenue
-  Go-forward SaaS bookings expectation of \$3M - \$5M per quarter
-  Anticipate reaching cash generation during 3Q 2023



Streamline  
Health®

First Quarter 2022 Earnings Presentation  
Nasdaq: STRM

